Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | TDO2 | P48775 | 2/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | PLG | P00747 | 2/20 | 0.45 |
| ▸ | KLK1 | P06870 | 2/20 | 0.45 |
| ▸ | KLK6 | Q92876 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31602938 | 0.85 | CSNK2A1 (0.60) | NPC1RAB9AGSK3BLMNAHTT | |
| SCHEMBL3233653 | 0.85 | CSNK2A1 (0.60) | NPC1RAB9AGSK3BLMNAHTT | |
| SCHEMBL3174922 | 0.84 | NPC1 (0.66) | NPC1RAB9AIDO1TDO2LMNA | |
| SCHEMBL1434608 | 0.82 | GSK3B (0.59) | NPC1RAB9AGSK3BLMNAHTT | |
| SCHEMBL30016132 | 0.82 | GSK3B (0.59) | NPC1RAB9AGSK3BLMNAHTT | |
| SCHEMBL9639259 | 0.82 | HSP90AB1 (0.69) | NPC1RAB9AIDO1TDO2LMNA | |
| SCHEMBL5055150 | 0.81 | GSK3B (0.52) | NPC1RAB9AGSK3BMAPTHPGD | |
| SCHEMBL3844607 | 0.80 | HSP90AB1 (0.66) | NPC1RAB9ALMNAHTTMAPT | |
| SCHEMBL31105825 | 0.80 | HSP90AB1 (0.66) | NPC1RAB9ALMNAHTTMAPT | |
| SCHEMBL22641046 | 0.79 | GSK3B (0.50) | NPC1RAB9AIDO1TDO2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860994-B1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2024-08-14 | — | — | EP | disclosed |
| US-20220106304-A1 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-04-07 | — | — | US | disclosed |
| WO-2021003295-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2010015652-A2 | THIAZOLE COMPOUNDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106304-A1 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | BRDT, CBFB, CREBBP | NPC1 4515/4885RAB9A 3925/4885IDO1 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.